Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Anti-Fel d1 IgY is a preparation of **immunoglobulin Y (IgY) antibodies** derived from the eggs of hens immunized with **Fel d1**, the major cat allergen. These IgY antibodies specifically bind to Fel d1 in the saliva of cats. When incorporated as an ingredient in cat food, anti-Fel d1 IgY binds and neutralizes Fel d1 in the oral cavity, thereby reducing active Fel d1 on the cat's haircoat (spread during grooming) and decreasing environmental allergen load. The mechanism is not direct immunomodulation in cats or humans, but physical blockade of the allergen, preventing it from binding human IgE and triggering allergic reactions. This strategy offers a novel dietary approach to reduce exposure to cat allergen, benefitting individuals allergic to cats.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on anti-fel-d1 igy.